HC Wainwright & Co. Maintains Buy on Disc Medicine, Maintains $70 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has maintained a Buy rating on Disc Medicine (NASDAQ:IRON), with a price target of $70.

March 22, 2024 | 2:57 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating and a $70 price target on Disc Medicine.
The maintenance of a Buy rating and a high price target by a reputable analyst firm like HC Wainwright & Co. typically signals a strong vote of confidence in the company's future performance. This can positively influence investor sentiment and potentially lead to an increase in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100